Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

BACKGROUND: Anamorelin HCl (ANAM) is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of cancer cachexia. We report in vitro and in vivo studies evaluating the preclinical pharmacologic profile of ANAM. METHODS: Fluorescent imaging plate reader and binding a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietra, Claudio, Takeda, Yasuhiro, Tazawa-Ogata, Naoko, Minami, Masashi, Yuanfeng, Xia, Duus, Elizabeth Manning, Northrup, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248409/
https://www.ncbi.nlm.nih.gov/pubmed/25267366
http://dx.doi.org/10.1007/s13539-014-0159-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248409/
https://www.ncbi.nlm.nih.gov/pubmed/25267366
http://dx.doi.org/10.1007/s13539-014-0159-5

Ejemplares similares